Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy

Autor: Ranjit Nair, Gaëlle Drillet, Faustine Lhomme, Anthony Le Bras, Laure Michel, John Rossi, Marika Sherman, Allen Xue, Anne Kerber, Nutchawan Jittapiromsak, Linda Chi, Sudhakar Tummala, Sattva S. Neelapu, Roch Houot

Publikováno v: Haematologica, Vol 106, Iss 5 (2020)

Externí odkaz: https://doaj.org/article/32393e9fbf384c0c998137ec79cf8509

Earlier corticosteroid use for adverse event management in patients receiving axicabtagene ciloleucel for large B‐cell lymphoma

Autor: Irit Avivi, Tom van Meerten, Jenny J. Kim, Marika Sherman, John M. Rossi, Roch Houot, Monique C. Minnema, Jinghui Dong, Martin Wermke, John Kuruvilla, Yan Zheng, Max S. Topp, Kevin W. Song, Saran Vardhanabhuti, Ulrich Dührsen, Adrian Bot, Marie José Kersten, Vicki Plaks, Anne Kerber, Catherine Thieblemont, Pieternella J. Lugtenburg, Krimo Bouabdallah

Publikováno v: British journal of haematology, 195(3), 388-398. Wiley-Blackwell
The Lancet. Oncology
British Journal of Haematology, 195(3), 388-398. Wiley
British Journal of Haematology, 195(3), 388-398. Wiley-Blackwell Publishing Ltd

Axicabtagene ciloleucel (axi-cel) is an autologous anti-CD19 chimeric antigen receptor (CAR) T-cell therapy approved for relapsed or refractory large B-cell lymphoma (R/R LBCL). To reduce axi-cel–related toxicity, several exploratory safety managem

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d221398e086175a1966d5df1db193e78
https://doi.org/10.1111/bjh.17673

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL)

Autor: Catherine Thieblemont, Marie José Kersten, Pieternella J. Lugtenburg, Anne Kerber, Ulrich Dührsen, Rachel Chu, Monique C. Minnema, John Kuruvilla, Noel Milpied, Martin Wermke, Max S. Topp, Tom van Meerten, Kevin W. Song, Vicki Plaks, Irit Avivi, Lianqing Zheng, Roch Houot

Background Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for the treatment (Tx) of patients (pts) with R/R LBCL with ≥ 2 prior systemic therapies. In Cohorts 1+2 (C1+2) of the ZUMA-1 study, Grade ≥ 3 c

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c19d0b75d3c254720346e3e08c672bdc
https://dspace.library.uu.nl/handle/1874/394926

Earlier Steroid Use with Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory Large B Cell Lymphoma

Autor: Roch Houot, Tom van Meerten, Marie José Kersten, Monique C. Minnema, Catherine Thieblemont, Anne Kerber, Lianqing Zheng, Ulrich Dührsen, Noel Milpied, John Kuruvilla, Pieternella J. Lugtenburg, Max S. Topp, Vicki Plaks, Rachel Chu, Irit Avivi, Martin Wermke, Kevin W. Song

Background: Axi-cel is an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy approved for the treatment (Tx) of patients (pts) with relapsed/refractory large B cell lymphoma (R/R LBCL) with ≥ 2 prior systemic therapies. In Cohorts

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3af3782fb5f098b04524b6d9fa13f08b

PRELIMINARY RESULTS OF EARLIER STEROID USE WITH AXICABTAGENE CILOLEUCEL (AXI-CEL) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B CELL LYMPHOMA

Autor: Max S. Topp, Monique C. Minnema, Martin Wermke, Marie-Jose Kersten, Kevin W. Song, T. van Meerten, Catherine Thieblemont, Anne Kerber, Vicki Plaks, Pieternella J. Lugtenburg, Yizhou Jiang

Publikováno v: Hematological Oncology. 37:305-305

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c910e2c1784de3e116d2c9e8da147fa2
https://doi.org/10.1002/hon.114_2630